Additionally, Epratuzamab, an anti-CD22 monoclonal IgG antibody, has been shown to be effective in moderate/severe active SLE, with phase III studies (the EMBODY studies) showing improvement in disease activity and bioactivity. The gene discussed is CD22; the disease is systemic lupus erythematosus.